摘要
基于表皮生长因子受体(EGFR)酪氨酸激酶抑制剂(TKI)的靶向治疗是携带EGFR突变型晚期非小细胞肺癌(NSCLC)患者的一线靶向治疗。目前,针对EGFR 19号外显子缺失和21外显子点突变等常见位点突变的TKI靶向治疗取得了显著疗效。然而,10%~20%的NSCLC患者携带罕见的EGFR位点突变,这些罕见突变位点对EGFR TKI治疗常不敏感。EGFR 20号外显子插入突变(EGFR ex20ins)是最常见的EGFR罕见突变之一,由于其结构的特异性,传统的TKI治疗并不适用于该类患者,目前尚无针对EGFR ex20ins NSCLC的有效治疗方法。因此,该领域的研究值得高度关注。
Targeted therapy based on epidermal growth factor receptor(EGFR)tyrosine kinase inhibitor(TKI)is a first-line targeted therapy for patients with advanced non-small cell lung cancer(NSCLC)carrying EGFR mutant.At present,TKI targeted therapy for common site mutations such as EGFR exon 19 deletion and exon 21 point mutation has achieved remarkable curative effect.However,10%-20%of NSCLC patients carry rare EGFR site mutations,which are often insensitive to EGFR TKI treatment.EGFR exon 20 insertion mutation(EGFR ex20ins)is one of the most common EGFR rare mutations.Due to its structural specificity,the traditional TKI treatment is not suitable for this kind of patients.At present,there is no effective treatment for EGFR ex20ins NSCLC.Therefore,the research in this field deserves high attention.
作者
朱晓莹
黄剑
ZHU Xiaoying;HUANG Jian(The Center of Pathological Diagnosis and Research,Affiliated Hospital of Guangdong Medical University,Zhanjiang 524001,China)
出处
《医学综述》
CAS
2022年第14期2801-2807,共7页
Medical Recapitulate
